NASDAQ-NMS:TXG

10x Genomics to Present at the BofA Securities 2024 Healthcare Conference

Retrieved on: 
Thursday, May 2, 2024
Bank of America, BofA Securities, Genomics, Conference, Interest

PLEASANTON, Calif., May 2, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, at 4:20 p.m. Pacific Time.

Key Points: 
  • PLEASANTON, Calif., May 2, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, at 4:20 p.m. Pacific Time.
  • Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/ .
  • The webcast will be archived and available for replay for at least 45 days after the event.

10x Genomics Reports First Quarter 2024 Financial Results

Retrieved on: 
Tuesday, April 30, 2024
Chromium, Genomics, Webcast, Information technology, 10x Genomics, Operating cost, Feedback, Growth, Architecture, Video game

PLEASANTON, Calif., April 30, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • PLEASANTON, Calif., April 30, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2024.
  • "We delivered four major new products this quarter, which set a new standard for single cell and spatial biology," said Serge Saxonov, Co-founder and CEO of 10x Genomics.
  • Gross margin was 66% for the first quarter of 2024, as compared to 73% for the corresponding prior year period.
  • 10x Genomics will host a conference call to discuss the first quarter 2024 financial results, business developments and outlook after market close on Tuesday, April 30, 2024 at 1:30 PM Pacific Time / 4:30 PM Eastern Time.

10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024

Retrieved on: 
Wednesday, April 10, 2024
News, 10x Genomics, Genomics, Webcast

PLEASANTON, Calif., April 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on Tuesday, April 30, 2024.

Key Points: 
  • PLEASANTON, Calif., April 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on Tuesday, April 30, 2024.
  • The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
  • The news release with the financial results will be accessible from the company's website prior to the conference call.
  • Live audio of the webcast will be available on the "Investors" section of the company website at: www.10xgenomics.com .

10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay

Retrieved on: 
Tuesday, March 26, 2024
Transcriptome, Histology, 10x Genomics, History, Space Ranger, Integration, Genomics, H&E, Gene expression, Microscope

PLEASANTON, Calif., March 26, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product. This assay enables researchers to measure the whole transcriptome from FFPE tissue sections at single cell-scale resolution.

Key Points: 
  • Began global shipments for Visium HD, a new product that enables whole transcriptome spatial discovery at single cell–scale resolution
    PLEASANTON, Calif., March 26, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product.
  • "Visium HD is a game-changer for spatial discovery research, and our team couldn't be more proud and excited to get this long-awaited product into the hands of our customers," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics.
  • Combining the power of whole transcriptome spatial discovery with histological insights, Visium HD enables comprehensive characterization of FFPE tissue samples.
  • Best-in-class sequencing-based spatial transcriptomics data: Map gene expression with precision and high confidence using a simple and robust workflow exclusively available on Visium CytAssist.

10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel

Retrieved on: 
Thursday, March 21, 2024
B cell, Oncogene, Tissue, Research, Tumor microenvironment, Cell membrane, University, Genomics, Escape Room, Medical imaging

PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications. These new products expand the breadth of the Xenium single cell spatial analysis menu.

Key Points: 
  • PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications.
  • These new products expand the breadth of the Xenium single cell spatial analysis menu.
  • The Xenium In Situ Cell Segmentation Kit improves the determination of cell boundaries by using a stain and algorithmic technique developed and validated through custom-trained machine learning models.
  • State-of-the-art, custom-built algorithm: Obtain more accurate cell segmentation with an advanced AI algorithm specifically trained on real-world Xenium cellular and tissue data.

10x Genomics Begins Commercial Shipments of Chromium GEM-X Products

Retrieved on: 
Wednesday, March 13, 2024
Associate, Transcriptome, Biology, University, Chromium, Architecture, Gene, Research, Genomics, Cell, Mobile phone

PLEASANTON, Calif., March 13, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3. GEM-X is the next generation of the company's leading single cell technology architecture and is built on a new and improved microfluidic chip design, featuring the latest technological advancements and optimized reagents for superior performance and high reliability.

Key Points: 
  • "It's been incredible to see the enthusiasm from customers since we first announced the GEM-X architecture last month, and we can't wait to get these new products in researchers' hands," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer of 10x Genomics.
  • "GEM-X sets a new standard for single cell analysis and gives customers important performance advantages that will immediately benefit their research.
  • This is one of multiple steps we have planned to make single cell more accessible for all."
  • "GEM-X, with its exceptional transcript capture, can enhance our capacity to differentiate cell types, spot rare cells and decode regulatory pathways.

10x Genomics to Present at the 44th Annual TD Cowen Health Care Conference

Retrieved on: 
Tuesday, February 20, 2024
Interest, Genomics, Conference

PLEASANTON, Calif., Feb. 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, at 2:50 p.m. Eastern Time.

Key Points: 
  • PLEASANTON, Calif., Feb. 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, at 2:50 p.m. Eastern Time.
  • Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/ .
  • The webcast will be archived and available for replay for at least 45 days after the event.

10x Genomics Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology

Retrieved on: 
Wednesday, February 7, 2024
Economics, Genomics, Chromium, Architecture, Next, Cell, Research

PLEASANTON, Calif., Feb. 7, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of GEM-X, the next generation of the company's leading single cell technology. The first major overhaul to the Chromium architecture since the 2019 launch of Next GEM technology, GEM-X is built on a new and improved microfluidic chip design, featuring the latest technological advancements and optimized reagents for superior performance and high reliability.

Key Points: 
  • GEM-X, the next generation of the company's leading single cell technology architecture, enables higher performance at larger scale and lower cost
    Pre-orders now open for first two Chromium products powered by GEM-X; expected to ship in Q1
    PLEASANTON, Calif., Feb. 7, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of GEM-X , the next generation of the company's leading single cell technology.
  • "With GEM-X, we are advancing our leadership in single cell analysis, raising the bar on performance and setting a new standard for the field," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer of 10x Genomics.
  • "This is a game-changing technology that will help drive better, faster and more cost effective single cell research and enable more academic and translational researchers to routinely rely on these tools to help resolve biology's complexity."
  • The company is now accepting preorders for the first two product launches powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3'v4 and Chromium Single Cell Immune Profiling 5'v3.

10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting

Retrieved on: 
Monday, February 5, 2024
Flex, Genomics, Growth, Glossary of biology, Cell, Cytokine, B cell, Mass meeting, Transcriptome, Gene expression, Protein, Biology, Tissue, CRISPR, Chromium, Multimodal, Microscope

PLEASANTON, Calif., Feb. 5, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a series of new products and technology demonstrations that will be presented at the 2024 Advances in Genome Biology and Technology (AGBT) General Meeting this week in Orlando, Florida.

Key Points: 
  • "The new products we have planned for 2024 will take 10x to the next level, as we deliver game-changing new technologies that will redefine the Visium, Xenium and Chromium platforms," said Ben Hindson, Co-founder and Chief Scientific Officer of 10x Genomics.
  • 10x Genomics will host a workshop at AGBT on Wednesday, February 7, at 1:10 p.m.
  • At AGBT, 10x Genomics will unveil new products, features and protocols designed to enable researchers with improved and more cost effective single cell workflows.
  • Throughout AGBT, 10x Genomics will demonstrate the use of its platforms to generate groundbreaking biological insights:
    Sponsor Workshop: Mind blowing science enabled by industry-leading single cell & spatial technologies (February 7, 2024).

10x Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Retrieved on: 
Wednesday, January 24, 2024
News, Genomics, Webcast

PLEASANTON, Calif., Jan. 24, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after market close on Thursday, February 15, 2024.

Key Points: 
  • PLEASANTON, Calif., Jan. 24, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after market close on Thursday, February 15, 2024.
  • The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
  • The news release with the financial results will be accessible from the company's website prior to the conference call.
  • Live audio of the webcast will be available on the "Investors" section of the company website at: www.10xgenomics.com .